Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 09, 2025 07:00 ET | Source: George Medicines

George Medicines announces FDA approval of WIDAPLIK™ (telmisartan, amlodipine and indapamide), a new single pill combination treatment for hypertension in adults, including initial treatment

Novel, single pill, triple combination with a standard dose and two lower doses that can deliver the efficacy benefits of combination therapy, with an established safety profile and good...
September 24, 2024 07:00 ET | Source: George Medicines

Potential of George Medicines’ novel, low-dose, triple combination pill to transform management of hypertension highlighted at global congress

London, UK 24 September 2024 – George Medicines, a late-stage, biopharmaceutical company addressing significant unmet need in the treatment of cardiometabolic disease, today announced the presentation...
August 31, 2024 03:54 ET | Source: George Medicines

George Medicines demonstrates potential of novel, low-dose, triple combination pill to transform management of hypertension in Hot Line Session at ESC Congress 2024

George Medicines demonstrates potential of novel, low-dose, triple combination pill to transform management of hypertension in Hot Line Session at ESC Congress 2024 Results from two Phase III trials...
August 06, 2024 07:00 ET | Source: George Medicines

George Medicines files New Drug Application with FDA for novel low dose triple combination for treatment of hypertension following successful international Phase III development program

George Medicines files New Drug Application with FDA for novel low dose triple combination for treatment of hypertension following successful international Phase III development program ...
April 29, 2024 07:00 ET | Source: George Medicines

George Medicines Appoints Mark Mallon as Chief Executive Officer and Board Director

George Medicines Appoints Mark Mallon as Chief Executive Officer and Board Director London, UK 29 April 2024 – George Medicines, a late-stage, biopharmaceutical company addressing significant unmet...
July 12, 2023 07:00 ET | Source: George Medicines

George Medicines completes recruitment of first Phase III hypertension trial investigating novel single-pill triple combination candidate GMRx2

George Medicines completes recruitment of first Phase III hypertension trial investigating novel single-pill triple combination candidate GMRx2 All patients enrolled in active-controlled trial...